WallStreetZen

NYSE: MRK
Merck & Co Inc Earnings & Revenue

MRK past earnings growth

How has MRK's earnings growth performed historically?
Company
-46.73%
Industry
22.33%
Market
96.23%
MRK's earnings have grown slower (3.53% per year) than the US Drug Manufacturers - General industry average (11.67%)
Performance
MRK's earnings have grown slower (3.53% per year) than the US market average (33.21%)
Performance
MRK's earnings growth is slowing down - its growth over the last year (-46.73%) is below its 5-year compound annual rate (3.53%)
Performance

MRK past revenue growth

How has MRK's revenue growth performed historically?
Company
6.29%
Industry
18.11%
Market
42.59%
MRK's revenue has grown slower (4.24% per year) than the US Drug Manufacturers - General industry average (5.44%)
Performance
MRK's revenue has grown slower (4.24% per year) than the US market average (19.59%)
Performance
MRK's revenue growth is accelerating - its growth over the last year (6.29%) is above its 5-year compound annual rate (4.24%)
Performance

MRK earnings and revenue history

Current Revenue
$48.5B
Current Earnings
$5.6B
Current Profit Margin
11.5%
MRK's has demonstrated consistent long-term earnings growth over the past 10 years (136.56%)
Performance

MRK Return on equity

Current Company
19.4%
Current Industry
33.2%
Current Market
23.1%
MRK's Return on Equity (19.4%) shows a company that is not efficient at transforming shareholder equity into returns
Performance

MRK Return on assets

Current Company
6.1%
Current Industry
7.3%
MRK is generating lower Return on Assets (6.1%) than the US Drug Manufacturers - General industry average (7.57%)
Performance

MRK Return on capital employed

Current Company
10.08%
Current Industry
11.7%
MRK has gotten more efficient at generating Return on Capital (10.08%) compared to 3 years ago (8.19%)
Performance

Merck & Earnings & Revenue FAQ

What were MRK's earnings last quarter?

On Invalid Date, Merck & (NYSE: MRK) reported Q2 2021 earnings per share (EPS) of $0.61, up 48.74% year over year. Total Merck & earnings for the quarter were $1.55 billion. In the same quarter last year, Merck &'s earnings per share (EPS) was $1.19.

What was MRK's earnings growth in the past year?

As of Q4 2021, Merck &'s earnings has grown -46.73% year over year. This is 69.06 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 22.33%. Merck &'s earnings in the past year totalled $5.57 billion.

What was MRK's revenue last quarter?

On Invalid Date, Merck & (NYSE: MRK) reported Q2 2021 revenue of $11.40 billion up 21.91% year over year. In the same quarter last year, Merck &'s revenue was $9.35 billion.

What was MRK's revenue growth in the past year?

As of Q4 2021, Merck &'s revenue has grown 6.29% year over year. This is 11.82 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 18.11%. Merck &'s revenue in the past year totalled $48.55 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.